+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Myeloproliferative Disorder Drug"

From
Myeloproliferative Disorders Drugs Market Report 2025 - Product Thumbnail Image

Myeloproliferative Disorders Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Myeloproliferative Disorder (MPD) is a type of cancer that affects the bone marrow and blood cells. It is characterized by an overproduction of white blood cells, red blood cells, and platelets. Treatment for MPD typically involves chemotherapy, radiation therapy, and/or targeted therapy. Oncology drugs used to treat MPD include interferon-alpha, hydroxyurea, anagrelide, and ruxolitinib. These drugs are used to reduce the production of abnormal cells, reduce the risk of blood clots, and reduce the risk of infection. There are several companies that produce and market drugs for the treatment of MPD. These include Novartis, Pfizer, Incyte, and Celgene. Other companies that specialize in oncology drugs include Bristol-Myers Squibb, Merck, and AstraZeneca. Show Less Read more